Anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC)

**Lung cancer**
Every year lung cancer causes 2.09 million deaths worldwide, more than any other cancer.¹

**ALK+ NSCLC**
In ALK+ NSCLC, the ALK fusion or rearrangement drives cancer cell growth and survival.⁴,⁵

**CNS metastases**
The central nervous system (CNS) is a common site of progression.⁹

**First-line treatments**¹¹
Most patients progress on the current standard of care within one year of treatment, and approximately 60% will develop CNS metastases.¹²,¹³

**References**
14. F. Hoffmann-La Roche Ltd. data on file.